The BOKITO-2B Study: Tenofovir DF Bone and Kidney Toxicity in patients with viral liver infection with hepatitis B virus. Incidence and reversibility.
- Conditions
- Chronic hepatitis BTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2011-004272-11-NL
- Lead Sponsor
- Erasmus MC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
all adult, cHBV-infected patients on tenofovir or entecavir or without treatment are eligable
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 180
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
HIV-infection
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method